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Abstract
Background: Information is sparse regarding the association between international travel and hospitalization with
non-typhoidal Salmonella bacteremia. The aim of this study was to determine the proportion, risk factors and
outcomes of travel-related non-typhoidal Salmonella bacteremia.
Methods: We conducted a 10-year population-based cohort study of all patients hospitalized with non-typhoidal
Salmonella bacteremia in three Danish counties (population 1.6 million). We used denominator data on Danish
travellers to assess the risk per 100,000 travellers according to age and travel destination. We used patients
contemporaneously diagnosed with travel-related Salmonella gastroenteritis as reference patients to estimate the
relative risk of presenting with travel-related bacteremia as compared with gastroenteritis. To evaluate clinical
outcomes, we compared patients with travel-related bacteremia and patients with domestically acquired
bacteremia in terms of length of hospital stay, number of extraintestinal focal infections and mortality after 30 and
90 days.
Results: We identified 311 patients hospitalized with non-typhoidal Salmonella bacteremia of whom 76 (24.4%)
had a history of international travel. The risk of travel-related bacteremia per traveller was highest in the age
groups 15-24 years (0.8/100,000 travellers) and 65 years and above (1.2/100,000 travellers). The sex- and age-
adjusted relative risk of presenting with bacteremia was associated with travel to Sub-Saharan Africa (odds ratio
18.4; 95% confidence interval [6.9-49.5]), the Middle East (10.6; [2.1-53.2]) and South East Asia (4.0; [2.2-7.5]). We
found high-risk countries in the same three regions when estimating the risk per traveller according to travel
destination. Patients hospitalized with travel-related bacteremia had better clinical outcomes than patients with
domestically acquired bacteremia, they had a shorter length of hospital stay (8 vs. 11 days), less extraintestinal focal
infections (5 vs. 31 patients) and a lower risk of death within both 30 days (relative risk 0.2; [0.1-0.7]) and 90 days
(0.3; [0.1-0.7]). A healthy traveller effect was a plausible explanation for the observed differences in outcomes.
Conclusions: International travel is a notable risk factor for being hospitalized with non-typhoidal Salmonella
bacteremia and the risk differs between age groups and travel destinations. Healthy travellers hospitalized with
bacteremia are less likely to have poor outcomes than patients with domestically acquired bacteremia.
Background
International travel has increased manifold during the
last decades as a consequence of increasing prosperity
and reduced costs. Overseas destinations have become
popular holiday resorts for Europeans, e.g., Thailand
was visited by 758,000 Scandinavians in 2007 [1]. As a
consequence there is increasing attention to the expo-
sure to parasitic and viral infections including malaria,
hepatitis, dengue fever, and HIV-infection [2-5]. Among
travel-related bacterial infections, typhoid and paraty-
phoid fevers have been addressed in a number of studies
[6-8]. Less information is available concerning invasive
infections with non-typhoidal Salmonella enterica sero-
vars (henceforth Salmonella) although they are common
causes of gastrointestinal infections in travellers. In a
recent Swedish study the highest risk of gastrointestinal
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Africa and the Indian subcontinent [9]. In a Danish
cohort study from the 1980’s, 18% of Salmonella bacter-
emias were associated with travel [10].
European studies on travel-related risk of Salmonella
bacteremia are few and either clinic-based [11,12] or con-
fined to a particular serovar or travel destination [13].
Therefore, the proportion of patients hospitalized with
travel-related bacteremia remains uncertain and knowl-
edge of potential risk factors and outcomes are lacking.
Such data would be of value for providers of guidance to
travellers and for clinical decision making. The objective
of this study was to determine the proportion of hospita-
lized patients with non-typhoidal Salmonella bacteremia
related to international travel, to assess whether the risk
of bacteremia was associated with the travel destination,
age or sex, and to evaluate the clinical outcome.
Methods
Study population
We conducted a population-based cohort study in the
three Danish counties of North Jutland, Aarhus and
Funen from January 1999 through December 2008
(average population 1.6 million, i.e. approximately one
third of the Danish population). The demographic com-
position was representative for all of Denmark.
The National Health Service provides tax-supported
health care free of charge to all Danish residents, provided
by general practitioners and public hospitals. People with
Danish citizenship or permanent residency in Denmark
a r eu n i q u e l yi d e n t i f i a b l eb ya10-digit civil registration
number, which is recorded at all contacts with the health
service allowing accurate linkage between health registries.
Data Sources
Local microbiological databases
In each county a single diagnostic laboratory processed
all bacteriological samples submitted by general practi-
tioners and hospitals. Information on blood isolates of
Salmonella serovars were retrieved from the electronic
laboratory information systems in each laboratory.
The National Registry of Enteric Pathogens (REP)
Diagnostic laboratories mandatorily report Salmonella
infections to the national reference center at Statens
Serum Institut (SSI) and this information is recorded in
the REP. If a Salmonella serovar is isolated more than
once from the same person within six months, only the
first positive sample is registered in the REP. Sample type
(feces, blood or another usually sterile site) is not avail-
able for all isolates. For the years 2004-2008 the database
holds information on international travel provided by the
local laboratory on a voluntarily basis. In 2008 full travel
information in REP was obtained by telephone interviews
[14]. The travel information collected by telephone
interviews and notified voluntarily has been found com-
parable with regard to the distribution of travel destina-
tions. We identified patients with Salmonella infection
who were residents in any of the three counties in the
REP.
Hospital charts
For patients hospitalized with non-typhoidal Salmonella
bacteremia, we extracted the following information: tra-
vel history, comorbidity, any extraintestinal site of infec-
tion, dates of admission and discharge, length of stay
and time of death. Comorbidity was classified according
to the Charlson comorbidity index and three levels of
comorbidity were defined: low (0), corresponding to
patients with no recorded underlying diseases; medium
(1-2) and high (≥3) [15].
Demographic data
Number of citizens in the three counties according to
age groups were available from Statistics Denmark and
used as denominators to calculate incidence rates [16].
Data on international travel
Statistics Denmark obtains information on international
travel from a random sample of approximately 500
Danish citizens contacted by telephone each month.
Information in the database includes age groups, travel
destinations, month of travel, type of travel (business or
pleasure), and length of travel. We restricted our ana-
lyses to pleasure travellers as business travellers may
have a different travel form and risk profile. To account
for a large number of short trips to neighboring coun-
tries, we included only travellers staying abroad for at
least three nights. We used the information in the data-
base to estimate travel patterns in the study population.
Estimated numbers by age group and country of travel
were used as denominators to calculate the risk of bac-
teremia per 100,000 travellers.
Laboratory procedures
Blood culture systems and nominal volumes of blood per
culture differed between regions (North Jutland County:
BacT/Alert (bioMérieux, Marcy I’Etoile, France) with a
blood volume of 3 × 10 mL; Aarhus County: BacT/Alert
(bioMérieux, Marcy I’Etoile, France); 2 × 20 mL; Funen
County: ESP (Trek Diagnostic Systems, Cleveland, Ohio,
USA) until 2001, and BACTEC (Becton Dickinson,
Franklin Lakes, NJ, USA) thereafter; 2 × 20 mL).
In North Jutland County fecal cultures were per-
formed by the regional diagnostic laboratory throughout
the study period [17]. In the counties of Aarhus and
Funen the regional laboratories carried out the cultures
from 2004 and 2006, respectively. Prior to that, fecal
cultures were performed by SSI, Copenhagen.
All Salmonella isolates obtained locally were referred
to the national reference laboratory at SSI for serotyping
according to the Kauffman-White scheme [18].
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We defined travel-related Salmonella bacteremia (hence-
forth TRB) on the basis of information in the hospital
chart regarding foreign travel prior to admission and lack
of any indication of domestic exposure. The remaining
bacteremias were defined as domestically acquired (hence-
forth DAB). If a patient had visited more than one destina-
tion, we defined the main travel destination as the country
where the patient had had an episode of diarrhea. If this
information was missing, the last visited country was
defined as the travel destination.
Ap a t i e n tw i t hSalmonella gastroenteritis was defined
as a patient recorded with non-typhoidal Salmonella in
the REP and no blood culture isolate recorded in the
local microbiological database.
Data analysis
Clinical data retrieved from patient charts were tabulated
in a spreadsheet. Relative prevalence proportions (RPP)
with corresponding 95% confidence intervals were calcu-
lated to estimate differences in age, sex and comorbidity
among patients with TRB compared to DAB. Risk esti-
mates per 100,000 travellers were calculated according to
travel destination and age groups (children 0-14, young
adults 15-24, adults 25-44, middle-aged 45-64, and elderly
≥65 years).
In the subset of patients diagnosed in 2004-2008, we
estimated the risk of TRB compared to travel-related
gastroenteritis by calculation of odds ratios (ORs) with
95% confidence intervals (CI). Risk associated with travel
region was estimated by logistic regression and age
group (<65, ≥65 years) and gender were included as
potential confounders.
STATA version 9.2 (College Station, Texas) was used
for the statistical analyses.
Ethics
The study was approved by The Danish National Board of
Health and the Danish Data Protection Agency (Record
no. 2008-54-0474).
Results
Demographic, clinical and bacteriological characteristics
During the 10-year study period a total of 350 patients
were hospitalized and diagnosed with Salmonella bactere-
mia. The following cases were excluded: Salmonella Typhi
(15), Salmonella Paratyphi (14) and non-residents (10),
leaving 311 patients with non-typhoidal Salmonella
bacteremia.
We identified 76 (24.4%) patients hospitalized with
TRB. Most (68/76, 89%) were admitted to hospital
within two weeks after returning to Denmark; patients
admitted later (8/76, 11%) had had diarrhea during
travel and fever after the return. Four of these patients
had been treated with antibiotics by their general practi-
tioner before hospital admission.
Table 1 presents key characteristics for patients with
TRB and DAB. In the group of patients with TRB there
was a majority of males and patients with TRB were
younger than patients with DAB (RPP for males in TRB
compared to DAB was 1.3; 95% CI[1.0-1.6]; RPP for age
<65 years was 1.6; [1.4-1.9]). Seventy one percent of
patients with TRB had no comorbidities according to
the Charlson index compared with 29% of patients with
DAB (RPP 2.4; [1.9-3.1]).
There were also notable differences in outcome
between the two groups of patients. Patients with TRB
had shorter length of hospital stay and fewer extraintest-
inal sites of infection than patients with DAB, e.g. osteo-
myelitis, infected aortic aneurysm, intraabdominal
abscess, or pleural empyema. The relative risk (RR) of
death within 30 days was lower among patients with
TRB (RR 0.2; [0.1-0.7]; RR of death after 90 days: 0.3;
[0.1-0.7]). This was due to a high mortality among
patients with DAB aged 65 years and above.
S. Enteritidis and S. Thyphimurium were among the
most common serovars identified from both patients
with DAB and TRB, together they counted for 55% and
37%, respectively. S. Dublin was the second most com-
mon serovar from patients with DAB (20%), but was
rare among patients with TRB. Conversely, few patients
with DAB had S. Virchow, which accounted for 10% of
the serovars from patients with TRB. In total, 34 differ-
ent serovars were identified among the domestically
acquired infections, and 30 among the group of travel-
related infections (Table 2).
Incidence and trends
Overall, the proportion of TRB was higher in the second
5-year period, 28.3% [range 25.7-32.5%], compared with
the first 5-year period, 20.8% [range 15.6-28.2%] (RPP
1993-2003 vs. 2004-2008: 1.4; [0.9-2.0]). Higher annual
numbers of DAB during the first period contributed to
this difference. The overall incidence rate of TRB was
0.5/100,000 person-years, with the highest incidence
rate in the age group 15-24 years (0.8/100,000 person-
years).
Seasonal patterns
Both DABs and TRBs showed a seasonal variation when
estimated within six periods of two months each. Most
cases of DABs were found in the autumn months,
September-October (59/235, 25%) and summer months,
July-August (52/235, 22%). Travel-associated cases had a
distinct peak in July-August (28/76, 37%), which were
the months with most travellers (Figure 1).
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Page 3 of 9Table 1 Characteristics of patients with travel-related (TRB) and domestically acquired (DAB) bacteremia
Characteristics TRB (n = 76) DAB (n = 235)
Age
Median (years, range) 36 (0-79) 64 (0-96)
<65 years (numbers, percent) 64 (84.2) 123 (52.3)
≥65 years 12 (15.8) 112 (47.7)
Sex
Males 49 (64.5) 118 (50.2)
Admitted to an infectious diseases unit
a 29/64 (45.3) 8/163 (4.9)
Comorbidity index
b
0 54 (71.1) 69 (29.4)
1-2 11 (14.5) 91 (38.7)
≥3 11 (14.5) 75 (31.9)
Individuals with malignancy
Hematological malignancies
c 3 (3.9) 23 (9.8)
Other malignancies 6 (7.9) 36 (15.3)
Other comorbidities
Dialysis
d 0 (0.0) 3 (1.3)
Organ transplantation 0 (0.0) 2 (0.9)
Alcoholism
e 3 (3.9) 21 (8.9)
Previous gastric surgery
f 3 (3.9) 5 (2.1)
Drug therapy
Chemotherapy & immunomodulatory agents 5 (6.6) 33 (14.0)
Corticosteroid therapy 2 (2.6) 30 (12.8)
PPI & H2-antagonist 7 (9.2) 66 (28.1)
Antacids 0 (0.0) 8 (3.4)
Length of hospital stay (median, IQR) 8 days (5-11) 11 days (6-17)
An extraintestinal site of infection 5 (6.6) 31 (13.2)
Mortality by age group
<65 years
30-day 3 (4.7) 11 (8.9)
90-day 4 (6.3) 12 (9.8)
≥65 years
30-day 0 (0.0) 30 (26.8)
90-day 1 (8.3) 40 (35.7)
Overall
30-day 3 (3.9) 41 (17.4)
90-day 5 (6.6) 52 (22.1)
a Only numbers from North Jutland and Aarhus Counties.
b Charlson comorbidity index.
c Lymphoma, leukaemia and myeloma; Patients with myeloproliferative disease or myelodysplastic syndrome also included.
d Dialysis due to complications to the bacteremia not included.
e Both history of present and previous alcoholism included.
f Gastrectomy, vagotomy, gastric bypass.
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Information on the duration of stay was available in (53/
76, 70%) of the TRB cases. The majority of patients had
travelled for less than three weeks (40/53, 75%), giving a
median stay of fourteen days (interquartile range (IQR)
9-21 days).
Patients hospitalized with TRB had travelled to 30 dif-
ferent countries. The highest numbers of TRBs were
contracted in Thailand (16), followed by Greece (6),
Spain (6), Egypt (5) and Turkey (5). Using data on travel
patterns for Danish tourists as denominator, we found
that the risk of hospitalization with Salmonella
bacteremia were different between age groups and travel
destinations (Table 3).
Relative risk of TRB compared to travel-related
gastroenteritis 2004-2008
From 2004-2008, we identified 2865 patients with Sal-
monella gastroenteritis in the REP after exclusion of
patients with bacteremia and cases of typhoid or paraty-
phoid fever. All patients were residents in one of the
three counties at the time of positive fecal cultures. Of
these, 527 (18.4%) patients were recorded as having tra-
vel-related Salmonella gastroenteritis.
Table 2 Serovars isolated from patients with travel-related (TRB) and domestically acquired (DAB) bacteremia
Serovar TRB Number (%) (n = 78)* Serovar DAB Number (%) (n = 235)
S. Enteritidis 23 (29.5) S. Enteritidis 84 (35.7)
S. Virchow 8 (10.3) S. Dublin 48 (20.4)
S. Typhimurium 6 (7.7) S. Typhimurium 46 (19.6)
S. Newport 4 (5.1) S. Bovismorbificans 6 (2.6)
S. Panama 4 (5.1) S. Newport 5 (2.1)
S. Aviana 3 (3.8) S. Agona 4 (1.7)
S. Saint-Paul 3 (3.8) S. Java 4 (1.7)
S. Corvallis 2 (2.6) S. Oranienburg 4 (1.7)
S. Haifa 2 (2.6) S. Infantis 3 (1.3)
S. Heidelberg 2 (2.6) S. Chester 2 (0.9)
S. Java 2 (2.6) S. Hadar 2 (0.9)
S. Poona 2 (2.6) S. Heidelberg 2 (0.9)
Others 17 (21.8) S. Poona 2 (0.9)
S. Saint-Paul 2 (0.9)
S. Thompson 2 (0.9)
Others 19 (8.1)
*Two patients had double infections with different serovars.
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Page 5 of 9Table 3 Estimated number of travellers and risk of bacteremia per 100,000 travellers by age groups and country (> 3 night stay)
Age group/Country* Number of travel-related bacteremias (TRB) (1999-2008) Estimated number of travellers† (1999-2008) Risk per 100,000 travellers (95% CI)
0-14 years 13 3,300,000 0.4 (0.2-0.7)
15-24 years 15 1,800,000 0.8 (0.5-1.4)
25-44 years 16 3,730,000 0.4 (0.3-0.7)
45-64 years 20 3,860,000 0.5 (0.3-0.8)
≥65 years 12 980,000 1.2 (0.7-2.2)
Spain 6 1,340,000 0.4 (0.2-1.0)
Sweden 1 780,000 0.1 (0.0-0.9)
Germany 3 690,000 0.4 (0.1-1.4)
Greece 6 670,000 0.9 (0.4-2.0)
Turkey 5 440,000 1.1 (0.5-2.8)
Poland 2 340,000 0.6 (0.1-2.4)
Portugal 3 310,000 1.0 (0.3-3.0)
Thailand 16 300,000 5.3 (3.3-8.7)
Egypt 5 260,000 1.9 (0.8-4.7)
Czech Republic 2 220,000 0.9 (0.2-3.7)
Bulgaria 2 130,000 1.5 (0.4-6.3)
Croatia 1 90,000 1.1 (0.2-8.1)
Vietnam 4 75,000 5.3 (1.9-15.0)
India 1 75,000 1.3 (0.2-9.7)
Mexico 1 60,000 1.7 (0.2-12.3)
United Arab Emirates 1 35,000 2.9 (0.4-21.7)
Ukraine 1 35,000 2.9 (0.4-21.5)
China 1 30,000 3.3 (0.4-25.5)
Tanzania 1 25,000 4.0 (0.5-31.2)
Malta 1 8000 12.5 (1.4-114.6)
Malaysia 1 7000 14.3 (1.5-137.3)
Ghana 2 6000 33.3 (5.6-199.5)
Senegal 1 6000 16.7 (1.7-160.2)
*Number of travellers to Kenya, Cambodia, Guatemala, Indonesia, Iraq, Somalia and Uganda were not available. Three cases of TRB were contracted in Kenya and one case in each of the other countries.
† Numbers for the age group 0-14 years were based on the proportion of adults travelling with children
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9We found Sub-Saharan Africa, the Middle East, and
S o u t hE a s tA s i at ob eh i g h - r i sk regions for contracting
TRB when compared to contemporary cases of travel-
associated Salmonella gastroenteritis. An increased risk
was also found in the age group of 65 years and above,
but there were no difference related to sex (Table 4).
Discussion
In this cohort study, we found that the overall incidence
of patients hospitalized with travel-related non-typhoidal
Salmonella bacteremia was low (0.5/100,000 person-
years). Still, one in four cases hospitalized with Salmo-
nella bacteremia in Denmark was associated with travel.
The risk was most pronounced for the elderly and the
young adult travellers and for travellers to countries in
the regions of Sub-Saharan Africa, the Middle East and
South East Asia. However, patients with travel-related
infections were less likely to have poor outcomes than
patients with domestically acquired infections. Our data
also suggested an increasing trend in the proportion of
TRBs, which is further supported by the previous Dan-
ish population-based study from the 1980s [10]. One
crucial factor is probably the major reduction in the
incidence of domestically acquired Salmonella infections
which followed implementation of a national Salmonella
control program in 1997 [19,20]. During the last three
decades the popularity of overseas travel has been
increasing and together these two trends are likely to
have changed the national ‘balance sheet’ for invasive
Salmonella infections.
Our study has a number of important limitations. First,
our study design only allowed for detection of Salmonella
infections among hospitalized patients and our results
were therefore based on estimates of the risk of being
hospitalized with bacteremia and not on the risk of falling
ill for which no data were available. Although, we believe
that our study included all severe cases of invasive Sal-
monella infections, patients withaf e v e ra n dah i s t o r yo f
international travel may have been hospitalized at a lower
threshold of clinical suspicion than patients with domes-
tically acquired infections. This would lead to a potential
overestimation of the proportion of TRB as compared
with DABs. Second, we only included patients with
bacteremia diagnosed after their return to Denmark. Tra-
vellers who were diagnosed and treated for bacteremia
abroad therefore did not appear in the data. Admission
and treatment at local hospitals may be more likely for
travellers staying abroad for extended periods and the
risk of bacteremia may therefore be biased towards desti-
nations typically associated with shorter stays. Third, we
were not able to validate the travel information given in
hospital charts which relied on the clinicians’ notes. If
bias were introduced, it would most likely be in the form
of ‘missing data’ on foreign travel. This would entail a
potential underestimation of the proportion of TRBs.
However, when considering the potential for misclassifi-
cation of the travel information, we still believe that the
different risk estimates reflect genuine differences in
exposure.
Previous studies have shown the greatest risk of non-
typhoidal Salmonella bacteremia at the extremes of age
and we expected to find the same age distribution among
patients with TRB [21]. Several predisposing comorbid-
ities are acknowledged risk factors for Salmonella bacter-
emia, e.g. chronic or immunosuppressing conditions,
including malignancy, rheumatological disease, liver dis-
ease, and diabetes [22-24], and it is likely that the ele-
vated risk of TRB in the elderly reflected an increased
prevalence of comorbidities in this age group. We used
the Charlson comorbidity index as a summary measure
of the patients’ comorbidities, which includes 19 major
disease categories, several of which are known risk factors
for Salmonella bacteremia. Comparison of the burden of
comorbidity in patients ≥65 years with that of patients
<65 years (data not included in the results) showed that
67% (8/12) of patients ≥65 years had one or more dis-
eases registered in the Charlson index compared with
only 22% (14/64) in patients <65 years (RPP for ≥1
comorbid disease: 3.0 [95% CI: 1.7-5.6]).
A previous study suggested that accommodation, tra-
vel characteristics, and dietary hygiene are important
factors for the evaluation of traveller’sr i s ko fd i a r r h e a
Table 4 Relative risk of travel-related bacteremia (TRB) compared to travel-related gastroenteritis, 2004-2008*
Variable Number of TRBs (n = 43) Odds ratio† 95% CI
Male 28 1.0 0.7-1.4
Age ≥65 years 6 5.3 3.7-7.6
Travel region‡ 7 18.4 6.9-49.5
Sub-Saharan Africa 2 10.6 2.1-53.2
Middle East 14 4.0 2.2-7.5
South East Asia
*Both voluntary and interview-based information were available during this period
†Adjusted for other risk factors in the model
‡Travel regions included in the analyses: East Asia & India, Eastern Europe & Russia, Middle East, Northern Africa, South East Asia, Southern Europe & Eastern
Mediterranean, Sub-Saharan Africa, The Americas, Western Europe & Nordic countries
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Page 7 of 9[25] and that the higher risk of traveller’s diarrhea found
in young adults may be associated with ingestion of lar-
ger volumes of potentially contaminated food and an
adventurous lifestyle in this age group [26]. These beha-
vioural factors would be important for the higher risk of
Salmonella bacteremia in young adults, although the
risk was only marginally higher than that reported for
other age groups. A formal analysis was not possible as
we had no data on behavioral factors or precise data on
travel form.
Comparison of the characteristics between patients
hospitalized with TRB and DAB (Table 1) illustrated that
the two groups were fundamentally different. There were
major differences in clinical outcomes between the
groups. Thus, patients with TRB had a shorter length of
hospital stay, fewer complications, and lower mortality
than patients with DAB. The explanation for the latter
observation is likely to be a “healthy traveller effect” as
illustrated by the lower prevalence of comorbidities in
the group of patients infected abroad. This is consistent
with a Swedish study on Salmonella-associated deaths
where persons infected domestically had a much more
severe prognosis than those infected abroad [27].
Earlier studies have shown that the distribution of sero-
v a r sm a yv a r ym u c hb yg e o g r a p h i cl o c a t i o na n dt i m e
[28,29]. Overall, S. Enteritidis was the predominant serovar
in Denmark throughout the study period, even though
S. Typhimurium was the most frequent serovar in the last
year of the study (2008) because of an unprecedented,
large nationwide outbreak [14]. S. Enteritidis was also the
most common serovar in Europe and dominant in most of
the travel regions [9]. This is in accordance with our find-
ing that S. Enteritidis was the most frequent serovar both
in patients with TRB and DAB. S. Virchow and S. Dublin
were the second most common serovars isolated from
patients with TRB or DAB, even though S. Typhimurium
were a much more common serovar in most regions of
the world. Both S. Virchow and S. Dublin show a higher
propensity for causing bacteremia and more severe infec-
tions than S. Typhimurium [21,30]. This suggests that the
distribution of serovars was due to both the overall abun-
dance of serovars as well as the exposure to more invasive
serovars.
Conclusions
International travel is an acknowledged risk factor for
non-typhoidal Salmonella gastroenteritis, however, little
is known regarding the risk of potentially more severe
invasive Salmonella infections. This study demonstrated
that international travel is a notable risk factor for being
hospitalized with non-typhoidal Salmonella bacteremia
and the risk differs among travellers according to age and
travel destination. Still, the overall risk is low and healthy
travellers with bacteremia are less likely to have poor
outcomes compared to patients with domestically
acquired bacteremia. Our findings may be useful for the
clinical evaluation of travellers presenting with fever and
may also support pre-travel counselling.
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